mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies.
By combining mAIbe’s AI-driven platform for antibody design and optimization with LenioBio’s cell-free expression technology, this partnership brings together two complementary strengths to significantly enhance the design–build–test cycle.
LenioBio’s ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbe’s AI models.
Through this integrated approach, the two teams will jointly:
- accelerate functional testing of AI-generated antibody candidates
- increase the efficiency and throughput of early validation
- enable faster iteration between computational predictions and experimental results
Together, mAIbe and LenioBio set a new standard for speed, flexibility, and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.
